Accéder au contenu
Merck
  • Improved human bioavailability of vemurafenib, a practically insoluble drug, using an amorphous polymer-stabilized solid dispersion prepared by a solvent-controlled coprecipitation process.

Improved human bioavailability of vemurafenib, a practically insoluble drug, using an amorphous polymer-stabilized solid dispersion prepared by a solvent-controlled coprecipitation process.

Journal of pharmaceutical sciences (2013-01-03)
Navnit Shah, Raman M Iyer, Hans-Juergen Mair, Duk Soon Choi, Hung Tian, Ralph Diodone, Karsten Fähnrich, Anni Pabst-Ravot, Kin Tang, Emmanuel Scheubel, Joseph F Grippo, Sebastian A Moreira, Zenaida Go, James Mouskountakis, Theresa Louie, Prabha N Ibrahim, Harpreet Sandhu, Linda Rubia, Hitesh Chokshi, Dharmendra Singhal, Waseem Malick
RÉSUMÉ

The present work deals with improving the solubility of vemurafenib, a practically insoluble drug, by converting it into an amorphous-solid dispersion using a solvent-controlled precipitation process. The dispersion containing vemurafenib and hypromellose acetate succinate (HPMCAS), an enteric polymer, is termed microprecipitated bulk powder (MBP), in which the drug is uniformly dispersed within the polymeric substrate. HPMCAS was found to be the most suitable polymer for vemurafenib MBP, among a series of enteric polymers based on superior physical stability and drug-release characteristics of the MBP. The MBP provided a greater rate and extent of dissolution than crystalline drug, reaching an apparent drug concentration of 28-35 µg/mL, almost 30-fold higher than solubility of crystalline drug at 1 µg/mL. The supersaturation was also maintained for more than 4 h. Upon exposure to high temperature and humidity, the MBP was destabilized, resulting in crystallization and lower dissolution rate. The control of moisture and temperature is essential to maintain the stability of the MBP. In a relative human bioavailability study, vemurafenib MBP provided a four- to fivefold increase in exposure compared with crystalline drug. Improving solubility with an amorphous-solid dispersion is a viable strategy for the development of practically insoluble compounds.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Methyl cellulose, viscosity: 4,000 cP
Sigma-Aldrich
(Hydroxypropyl)methyl cellulose, viscosity 2,600-5,600 cP, 2 % in H2O(20 °C)(lit.)
Sigma-Aldrich
Methyl cellulose, viscosity: 15 cP, BioReagent, suitable for cell culture
Sigma-Aldrich
Methyl cellulose, viscosity: 1,500 cP
Sigma-Aldrich
(Hydroxypropyl)methyl cellulose
Sigma-Aldrich
(Hydroxypropyl)methyl cellulose, viscosity 80-120 cP, 2 % in H2O(20 °C)(lit.)
Sigma-Aldrich
(Hydroxypropyl)methyl cellulose, average Mn ~10,000
Sigma-Aldrich
(Hydroxypropyl)methyl cellulose, viscosity 40-60 cP, 2 % in H2O(20 °C)(lit.)
Sigma-Aldrich
Methyl cellulose, viscosity: 15 cP
Sigma-Aldrich
(Hydroxypropyl)methyl cellulose, average Mn ~120,000
Sigma-Aldrich
Methyl cellulose, viscosity: 25 cP
Sigma-Aldrich
Methyl cellulose, 27.5-31.5% (Methoxyl content), viscosity: 400 cP
Sigma-Aldrich
(Hydroxypropyl)methyl cellulose, average Mn ~86,000
Sigma-Aldrich
Hypromellose, meets USP testing specifications
Sigma-Aldrich
(Hydroxypropyl)methyl cellulose, average Mn ~90,000
Sigma-Aldrich
Methyl cellulose, meets USP testing specifications, 26.0-33.0% (methoxyl group, on Dry Basis), viscosity: 400 cP
Sigma-Aldrich
Methyl cellulose, 26.0-33.0% (Methoxy group (dry basis)), meets USP testing specifications, viscosity: 1,500 cP
Sigma-Aldrich
Methyl cellulose, viscosity 3000-5500 mPa.s, 2 % in H2O(20 °C)
Sigma-Aldrich
Methyl cellulose, medium viscosity, Methoxyl content 27.5-31.5 %
Sigma-Aldrich
Methyl cellulose, tested according to Ph. Eur.
Sigma-Aldrich
Methyl cellulose, 27.5-31.5% methoxyl basis